Masimo Co. (NASDAQ:MASI) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Masimo Co. (NASDAQ:MASI) have been assigned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $179.67.

Several equities research analysts recently commented on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a report on Wednesday, November 6th. BTIG Research lifted their price target on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Stifel Nicolaus reissued a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Raymond James lifted their target price on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research note on Friday, December 27th. Finally, Piper Sandler increased their price target on shares of Masimo from $180.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 18th.

Institutional Trading of Masimo

Several institutional investors have recently added to or reduced their stakes in the stock. NBC Securities Inc. boosted its position in Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 73 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 200 shares in the last quarter. GAMMA Investing LLC lifted its stake in Masimo by 136.5% in the fourth quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider’s stock worth $77,000 after acquiring an additional 269 shares during the last quarter. HHM Wealth Advisors LLC grew its holdings in Masimo by 25.0% during the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after acquiring an additional 125 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of Masimo in the 2nd quarter valued at approximately $109,000. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Stock Down 3.7 %

Shares of MASI opened at $165.55 on Wednesday. The stock has a 50 day moving average price of $166.17 and a 200 day moving average price of $137.76. Masimo has a one year low of $101.61 and a one year high of $180.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The stock has a market capitalization of $8.86 billion, a price-to-earnings ratio of 114.17 and a beta of 1.01.

Masimo (NASDAQ:MASI) last issued its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.63 earnings per share. Equities research analysts forecast that Masimo will post 4.03 earnings per share for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.